Content about Dr. Reddy's Laboratories

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs will move into a new North America headquarters and set up new laboratory space later this year, the company said Tuesday.

The India-based company said it had entered into two lease agreements for a new headquarters and research-and-development center in Princeton, N.J. These include a 75,500-sq.-ft. office space at 107 College Rd East and a 31,000-sq.-ft. office and laboratory at 303 College Rd East.

HYDERABAD, India — Indian generic drug maker Dr. Reddy's Labs has appointed G.V. Prasad as chairman of the company, Dr. Reddy's said Tuesday.

Prasad is currently vice chairman and CEO and will continue as chairman and CEO.

Meanwhile, Satish Reddy has been appointed vice chairman in addition to his current role as managing director and COO.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a drug used to treat certain cancers, the company said Tuesday.

Dr. Reddy's announced the launch of injectable zoledronic acid in the 4-mg-per-5-mL strength. The launch followed the Food and Drug Administration's approval of the drug.

The drug is a generic version of Novartis' Zometa. The drug is used to treat cancers that have spread to the bones and multiple myeloma.

CORRECTION: An earlier version of this story misstated the strength of the drug. The story has been corrected.

 SILVER SPRING, Md. - The Food and Drug Administration has given tentative approval to a generic drug for treating hypertension, according to agency records.

The FDA granted tentative approval to Dr. Reddy's Labs' valsartan tablets in the 40 mg, 80 mg, 160 mg and 320 mg strengths.

The drug is a generic version of Novartis' Diovan. Various versions of the drug had sales of $1.6 billion during the 12-month period that ended in June, according to IMS Health.

PRINCETON, N.J. — Novo Nordisk has appointed Curtis Oltmans as its corporate VP and general counsel for legal and quality affairs, the company said Friday.

In the new role, for which he will also join the company's U.S. executive team, Oltmans will be handle issues like law, quality, intellectual property, grants and philanthropy for the Danish drug maker's North American business.

HYDERABAD, India — Dr. Reddy's Labs has appointed a new CFO and head of its North America business, the generic drug maker said.

Dr. Reddy's said Umang Vohra will take over the role of EVP and head of generics for North America, starting in January 2013. Vohra has been CFO of Dr. Reddy's for the past four years.

Saumen Chakraborty will take over as CFO of Dr. Reddy's following Vohra's reappointment. Chakraborty is currently president and global head of quality, human resources, information technology and business process excellence.

The year 2012 is coming to an end, and it’s been a big year for 
generic drugs.


HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating asthma and allergies, and preventing bronchospasm during exercise, the company said.

The Indian company announced the launch of montelukast sodium oral granules in the 4-mg strength in unit-dose cartons of 30 packets.

The drug is a version of Merck's Singulair oral granules, which had sales of about $61 million during the 12-month period ended in July, according to IMS Health.

For branded drug makers, the pharmaceutical patent cliff has never loomed higher or steeper. The exposure of so many of the world’s biggest-selling medicines to generic competition for the first time is redefining the pricing model for many of the most widely prescribed classes of pharmaceuticals — reducing costs for health plans, payers and patients; scrambling drug makers’ balance sheets; and potentially boosting both drug utilization and adherence rates as reduced out-of-pocket costs induce more patients to fill their prescriptions.


The U.S. healthcare system presents a paradox: It’s the most expensive system in the world, and yet it produces among the worst results among developed countries. According to the most recent report from the National Health Expenditure Accounts, spending on health care reached $2.6 trillion in 2010, or more than $8,400 per person and around 18% of the country’s gross domestic product.


HYDERABAD, India — Dr. Reddy's Labs has launched a generic version of a popular cholesterol drug.

The company announced Wednesday the launch of atorvastatin calcium tablets in the 10-mg, 20-mg, 40-mg and 80-mg strengths.

The drug is a generic version of Pfizer's Lipitor, which had sales of slightly more than $8 billion during the 12-month period ended in March, according to IMS Health.

HYDERABAD, India — Dr. Reddy's Labs has launched a drug for treating Parkinson's disease, the company said Thursday.

Dr. Reddy's introduced ropinirole hydrochloride extended-release tablets in the 2-mg, 4-mg, 6-mg, 8-mg and 12-mg strengths. The 2-mg, 4-mg and 6-mg strengths will be available in 30- and 90-count bottle sizes, while the other two strengths will be available in 30-count bottles.

The drug is a generic version of GlaxoSmithKline's Requip XL, which had sales of $58 million during the 12-month period ended in March, according to IMS Health.